Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
B7ZC32
UPID:
KIF28_HUMAN
Alternative names:
Kinesin-like protein 6
Alternative UPACC:
B7ZC32
Background:
Kinesin-like protein KIF28P, also known as Kinesin-like protein 6, plays a pivotal role in cellular dynamics, specifically in the morphology and transport of mitochondria within neuronal cells. This microtubule-dependent motor protein is essential for maintaining the proper function and distribution of mitochondria, which are critical for energy production and cellular health.
Therapeutic significance:
Understanding the role of Kinesin-like protein KIF28P could open doors to potential therapeutic strategies. Its crucial function in mitochondrial transport and morphology underscores its potential as a target for addressing neurological disorders where mitochondrial dysfunction is a contributing factor.